ARK 每周股评 – 8/13/2022

我们每周都会与投资者分享我们策略中一周内一天内升值或下跌超过15%的股票的周评。我们希望您觉得这篇评论有用。

We share weekly commentaries with investors on stocks in our strategies that have appreciated or dropped more than 15% in a day during the course of the week. We hope you find this commentary useful.

Monday.Com Ltd (MNDY)
+18%Shares of Monday.com traded up ~18% on Monday after the company announced second-quarter earnings and increased full year revenues by roughly 5%. In the quarter, revenue increased 75% year-over-year, while net dollar retention exceeded 125%. ARK’s conviction is increasing that Monday.com is a leader among modern productivity and collaboration suites.

注:周一,Monday.com的股价上涨了约18%,此前该公司宣布了第二季度的收益,并将全年的收入增加了约5%。在该季度,收入同比增长75%,而净美元留存率超过125%。ARK越来越相信,Monday.com是现代生产力和协作套件中的领导者。
Nextdoor Holdings Inc. (KIND)
-25%Shares of Nextdoor traded down ~25% on Wednesday after the company reported second-quarter earnings and reduced guidance. On a year-over-year basis, revenue grew 20% and weekly active users (WAUs) increased 26% to 37 million. Management guided to revenue growth of 16% for the year. While ARK expects growth to decelerate across social media platforms as consumers and small businesses adjust to a post-COVID normal, we also believe that Nextdoor could become the hyper-local platform of choice. Nextdoor is a social media platform that connects local consumers, businesses, and public services.

注:周三,Nextdoor的股票下跌了25%,因为该公司公布了第二季度的收益并降低了指导价。按年计算,收入增长20%,每周活跃用户(WAUs)增长26%,达到3700万。管理层指导今年的收入增长为16%。虽然ARK预计,随着消费者和小企业适应COVID后的正常情况,整个社交媒体平台的增长将减速,但我们也相信,Nextdoor可能成为超本地平台的首选。Nextdoor是一个连接当地消费者、企业和公共服务的社交媒体平台。
Velo3D Inc. (VLD)
+42%Shares of Velo3D traded up ~42% on Wednesday after the company reported that second-quarter sales more than doubled year-over-year. Velo3D is a leading additive manufacturing and 3D-printing company specializing in support-free powder bed fusion. SpaceX is its largest customer and a strategic investor.

注:Velo3D的股价在周三上涨了约42%,此前该公司报告称第二季度的销售额同比增长了一倍多。Velo3D是一家领先的增材制造和3D打印公司,专门从事无支撑粉末床熔融。SpaceX是其最大的客户和战略投资者。
Vuzix Corp (VUZI)
+16%Shares of Vuzix traded up ~16% on Wednesday after the company reported second-quarter results. Management announced that Vuzix has signed fifteen contracts across the defense, consumer, and enterprise sectors, including four Fortune 100 retailers. Thanks to one of the contracts, Vuzix has begun to scale production of its M400 smart glasses to satisfy increased demand from Amazon’s warehouses. We have high conviction in Vuzix's ability to expand across verticals as the demand for augmented reality (AR) hits inflection points. Vuzix designs and manufactures AR glasses as well as related software and hardware for both consumers and enterprises globally.

注:周三,Vuzix的股票在该公司公布第二季度业绩后交易量上升了约16%。管理层宣布,Vuzix已经签署了15份合同,涉及国防、消费和企业领域,包括四家财富100强零售商。得益于其中一份合同,Vuzix已经开始扩大其M400智能眼镜的生产规模,以满足亚马逊仓库增加的需求。我们对Vuzix在增强现实(AR)的需求达到拐点时在各垂直领域的扩张能力有很强的信心。Vuzix为全球消费者和企业设计和制造AR眼镜以及相关软件和硬件。
Butterfly Network Inc. (BFLY)
+28%Shares of Butterfly Network traded up ~28% on Thursday, participating in a broad-based biotech rally. Butterfly Network is an innovative medical imaging company focused on commercializing a portable, low-cost point-of-care ultrasound (POCUS) system.

注:蝴蝶网络的股票周四上涨了约28%,参与了基础广泛的生物技术反弹。蝴蝶网络是一家创新的医疗成像公司,专注于将便携式、低成本的医疗点超声(POCUS)系统商业化。
Invite Corp (NVTA)
+280%Shares of Invitae traded up ~280% on Thursday after the company announced second-quarter earnings. We believe a combination of factors drove the stock price surge: a detailed and constructive quarterly earnings call, better-than-anticipated macro inflation reports, and a short squeeze impacting 22% of the liquid shares, or float, held short. The stock then traded down ~47% on Thursday before appreciating ~19% on Friday.In our view, Invitae’s recent portfolio consolidation and staff reductions have tilted the company toward profitability. While it still intends to offer one of the broadest and highest-quality molecular diagnostic testing menus and unique, population-scale digital health tools, unsettled market conditions are preventing Invitae from investing as aggressively in the genomic revolution as it had intended. That said, we are encouraged by the sustained improvements across key performance metrics, including revenue/patients, operating expenses as a percent of revenue, and gross margins. Invitae is a leading medical genetics testing company, thanks to its scalable variant interpretation engine, suite of digital and clinical services, and innovation in liquid biopsy.

注:周四,在公司宣布第二季度收益后,Invitae的股票交易量上升了约280%。我们认为,一系列因素推动了股价的飙升:详细而富有建设性的季度财报电话会议,好于预期的宏观通胀报告,以及影响22%的流通股(即浮动股)的空头挤兑。在我们看来,Invitae最近的投资组合整合和裁员已经使该公司向盈利能力倾斜。虽然它仍然打算提供最广泛和最优质的分子诊断测试菜单之一,以及独特的、人口规模的数字健康工具,但不稳定的市场条件使Invitae无法像它打算的那样积极地投资于基因组学革命。尽管如此,我们对关键业绩指标的持续改善感到鼓舞,这些指标包括收入/患者、运营费用占收入的百分比和毛利率。Invitae是一家领先的医学遗传学测试公司,这要归功于其可扩展的变体解释引擎、数字和临床服务套件以及液体活检的创新。
Pacific Biosciences Inc. (PACB)
+15%Shares of Pacific Biosciences traded up ~15% on Thursday in a broad-based biotech rally propelled by better-than-anticipated inflation data. Despite foreign exchange and pandemic-related headwinds, we were encouraged that PacBio’s revenue increased more than 50% in the Americas region this quarter—the highest growth rate of any sequencing company during this period––and are confident that its new long- and short-read systems will stimulate more revenue growth and profitability. According to our research, PacBio is the only sequencing company with two sensing platforms and chemistries, which should generate best-in-class data for any sequencing application. Pacific Biosciences is a leading provider of accurate and comprehensive sequencing solutions.

注:在通货膨胀数据好于预期的推动下,太平洋生物科学公司的股票周四在广泛的生物技术反弹中上涨了约15%。尽管有外汇和与大流行病有关的不利因素,我们感到鼓舞的是,PacBio本季度在美洲地区的收入增长了50%以上--是这一时期所有测序公司中增长率最高的--并相信其新的长读和短读系统将刺激更多的收入增长和盈利能力。根据我们的研究,PacBio是唯一一家拥有两种传感平台和化学品的测序公司,这应该为任何测序应用产生最佳的数据。太平洋生物科学公司是准确和全面的测序解决方案的领先供应商。
Personalis Inc. (PSNL)
+18%Shares of Personalis traded up ~18% on Thursday, participating in a broad-based biotech rally. Personalis provides immune-oncology (IO) diagnostic assays for biopharmaceutical developers.

注:周四Personalis股价上涨约18%,参与了基础广泛的生物技术反弹。Personalis为生物制药开发商提供免疫肿瘤学(IO)诊断测定。

主题测试文章,只做测试使用。发布者:star,转转请注明出处:https://wallstreetgm.com/ark-%e6%af%8f%e5%91%a8%e8%82%a1%e8%af%84-8-13-2022/

(0)
上一篇 2022年8月15日 上午9:37
下一篇 2022年8月17日 上午8:18

相关推荐

发表回复

您的电子邮箱地址不会被公开。